This dataset tracks 1,499 patent families filed between 2015 and the 2026 data cut-off, using a search that combines insulin pump, insulin delivery and artificial pancreas terminology with the core infusion-hardware IPC codes A61M5/142, A61M5/172 and A61M5/168. Family counts are the fairer unit here because they neutralise continuation filings and multi-jurisdiction duplicates of the same invention. The true figure for the most recent one to two years will rise further as filings still in the publication pipeline become visible.

No, filing activity peaked at 138 in 2017 and has not returned to that level since, with the 2022 midpoint sitting at 108. That is a flat-to-declining trajectory across the observed window rather than continued growth. The final couple of years in any chart understate true filing volume because of an approximate 18-month publication lag, but the multi-year plateau shown here predates that effect and is unlikely to be explained away by it alone.

A61M (devices for body fluids) is the anchor class, appearing in 1,494 of 1,499 records, confirming this is primarily an infusion-hardware dataset. G16H healthcare informatics is a close second at 798 records, followed by A61B diagnosis and surgery at 679, meaning dosing algorithms and monitoring integration are claimed almost as heavily as the physical pump mechanism. G06F, A61K, G01N, G16Z and G05B trail well behind and represent narrower, more specific claim territory.